Triple-negative breast cancer trials in France

In France 44 Also abroad 425

44 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Where
Limoges, Lyon, Montpellier, Paris, Reims, Rouen, Saint-Herblain, Toulon
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00
Phase 3Taking people
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Where
Amiens Cedex 1, Creteil Cedex, Dijon, Marseille, Montpellier, Paris, Pierre-Bénite, Rennes Cedex, Saint-Cloud
Age
18 years and over
People
2,400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Where
Lyon, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
1,132 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Where
Angers, Bayonne, Bordeaux, Brest, Caen Cedex 5, Clermont-Ferrand, Dijon, Guilherand-Granges, Levallois-Perret, Lyon, Marseille, Nice Cedex 2, Paris Cedex 20, Pau, Rouen, Saint-Herblain, Valenciennes
Age
18 years and over
People
1,530 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00
Phase 1Taking people
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Where
Poitiers, Villejuif Cedex
Age
18 years and over
People
260 worldwide
Run by
Pfizer
See details and how to joinNCT07318805 · EU 2025-524387-38-00
Phase 3Taking people
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Where
Amiens Cedex 1, Angers, Chambray-Les-Tours, Dijon, Le Mans, Limoges, Lyon, Nancy, Nantes Cedex 2, Nimes Cedex 9, Plérin, Poitiers, Rennes Cedex, Saint-Herblain Cedex, Strasbourg, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
1,514 worldwide
Run by
Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Lyon, Saint-Herblain Cedex, Toulouse Cedex 9
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Villejuif
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 3Taking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Angers, La Chaussee St Victor, Marseille, Nancy, Nice Cedex 2, Paris, Pierre-Bénite, Rennes Cedex, Saint-Cloud, Strasbourg, Villejuif
Age
18 years and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
Phase 2Taking people
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Where
Angers, Caen Cedex 5, Lille, Lyon, Plerin, Saint-Herblain Cedex, Strasbourg, Villejuif Cedex
Age
18 years and over
People
61 worldwide
Run by
Swiss Cancer Institute
See details and how to joinNCT06358573 · EU 2024-512511-49-00
Phase 1Not yet taking people in France
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Lyon, Marseille
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
No phaseNot yet taking people in France
Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast Cancer
Where
Aix-en-Provence, Briis-sous-Forges, Lyon, Marseille, Montpellier, Neuilly-sur-Seine, Paris
Age
18 years and over
People
144
Run by
FASTEN
See details and how to joinNCT07884721
Phase 1Taking people
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Where
Vandœuvre-lès-Nancy
Age
18 years and over
People
180 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07261631
Phase 2Not yet taking people in France
Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer
Where
Avignon, Bordeaux, Marseille, Nice Cedex 2, Paris Cedex 20, Toulouse
Age
18 years and over
People
84
Run by
Institut Paoli-Calmettes
See details and how to joinNCT07857486 · EU 2025-525040-18-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Bordeaux, Clermont-Ferrand, Lyon, Nîmes, Saint-Herblain, Strasbourg, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
No phaseNot yet taking people in France
Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.
Where
Nice
Age
18 years and over
People
50
Run by
Centre Antoine Lacassagne
See details and how to joinNCT07847398
Phase 3Taking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Where
Lille, Lyon, Montpellier, Paris, Saint-Herblain, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
625 worldwide
Run by
AstraZeneca
See details and how to joinNCT06103864
Phase 3Taking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Where
Lille, Lyon, Montpellier Cedex 5, Paris Cedex 20, Saint-Herblain Cedex, Toulouse Cedex 9, Vandouvre Les Nancy, Villejuif
Age
18 years and over
People
58 worldwide
Run by
AstraZeneca AB
See details and how to join2023-503675-24-00 · EU 2023-503675-24-00
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Where
Bordeaux, Caen, Lyon, Marseille, Montpellier, Nice, Paris, Villejuif
Age
18 years and over
People
416 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06618287
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Lyon, Paris, Saint-Herblain, Villejuif
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
Phase 1Taking people
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Where
Lyon, Marseille, Toulouse, Vandoeuvre Les Nancy Cedex
Age
18 years and over
People
62 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00
Phase 1/2Taking people
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Where
Paris, Villejuif
Age
18 years and over
People
250 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06657222 · EU 2025-522517-35-00
Phase 1/2Taking people
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Where
Clermont Ferrand Cedex1, Dijon, La Tronche, Lyon, Marseille, Nantes, Pessac, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
270 worldwide
Run by
Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00
Phase 2/3Taking people
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Where
Bordeaux, Clermont Ferrand Cedex1, Dijon, Lille, Lyon, Marseille, Montpellier, Poitiers, Rennes Cedex, Saint-Herblain Cedex, Villejuif
Age
18 years and over
People
600 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00
Phase 2Not yet taking people in France
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
Where
Albi, Angers, Arras Cedex, Avignon, Beauvais, Bordeaux, Caen Cedex 5, Chambray-lès-Tours, Chauny, Clermont-Ferrand, Clermont Ferrand Cedex 2, Dechy, Dijon, Eaubonne, Epagny Metz-tessy, Frejus, Lille, Limoges, Lyon, Marseille, Montpellier, Nantes Cedex 2, Nice Cedex 2, Osny, Paris, Poitiers, Reims, Saint-Cloud, Saint-Herblain Cedex, Saint-Priest-en-Jarez, St Nazaire, Strasbourg, Thonon-Les-Bains, Toulouse, Valence, Vandouvre Les Nancy, Villefranche Sur Saone Cedex, Villejuif
Age
18 years and over
People
260
Run by
UNICANCER
See details and how to joinNCT07151586 · EU 2025-521909-40-00